Birth outcomes after prenatal exposure to antidepressant medication

被引:127
作者
Hendrick, V
Smith, LM
Suri, R
Hwang, S
Haynes, D
Altshuler, L
机构
[1] Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Los Angeles, CA 90024 USA
[2] Harbor UCLA Med Ctr, Dept Pediat, Los Angeles, CA USA
[3] W LA Vet Affairs Med Ctr, Los Angeles, CA USA
关键词
antidepressant medication; pregnancy; birth outcome;
D O I
10.1067/mob.2003.172
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The purpose of this study was to examine prospectively the incidence of congenital anomalies and neonatal complications after prenatal exposure to antidepressant medication. STUDY DESIGN: Birth outcomes were obtained from a review of obstetric and neonatal records of 138 women who were treated with selective serotonin reuptake inhibitor antidepressant medications (SSRIs) during pregnancy. RESULTS: The incidence of congenital anomalies in this study was 1.4%, comparable to general population rates. Rates of low birth weight and preterm births were low, occurring in 2.9% and 6.5% of births, respectively. The low birth weight infants had been exposed to relatively high doses of fluoxetine (40-80 mg/d) throughout pregnancy. Average maternal weight gain in pregnancy was comparable across the three major medication categories (fluoxetine, paroxetine, sertraline). CONCLUSION: After prenatal use of selective serotonin reuptake inhibitor antidepressant medications, neonatal complications and congenital anomalies appear to occur within general population rates. However, maternal use of high doses of fluoxetine throughout pregnancy may be associated with a risk for low birth weight.
引用
收藏
页码:812 / 815
页数:4
相关论文
共 13 条
[1]   Frequency of septum pellucidum anomalies in non-psychotic population:: a magnetic resonance imaging study [J].
Aldur, MM ;
Gürcan, F ;
Basar, R ;
Aksit, MD .
SURGICAL AND RADIOLOGIC ANATOMY, 1999, 21 (02) :119-123
[2]   Hirschsprung disease, associated syndromes, and genetics: a review [J].
Amiel, J ;
Lyonnet, S .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (11) :729-739
[3]  
BENEDETTI TJ, 1978, OBSTET GYNECOL, V52, P526
[4]   Birth outcomes in pregnant women taking fluoxetine [J].
Chambers, CD ;
Johnson, KA ;
Dick, LM ;
Felix, RJ ;
Jones, KL .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1010-1015
[5]   Birth outcomes following prenatal exposure to fluoxetine [J].
Cohen, LS ;
Heller, VL ;
Bailey, JW ;
Grush, L ;
Ablon, JS ;
Bouffard, SM .
BIOLOGICAL PSYCHIATRY, 2000, 48 (10) :996-1000
[6]   Delivery outcome after the use of antidepressants in early pregnancy [J].
Ericson, A ;
Källén, B ;
Wiholm, BE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (07) :503-508
[7]   Effects of first-trimester fluoxetine exposure on the newborn [J].
Goldstein, DJ ;
Corbin, LA ;
Sundell, KL .
OBSTETRICS AND GYNECOLOGY, 1997, 89 (05) :713-718
[8]   Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors - A prospective controlled multicenter study [J].
Kulin, NA ;
Pastuszak, A ;
Sage, SR ;
Schick-Boschetto, B ;
Spivey, G ;
Feldkamp, M ;
Ormond, K ;
Matsui, D ;
Stein-Schechman, AK ;
Cook, L ;
Brochu, J ;
Rieder, M ;
Koren, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (08) :609-610
[9]  
Martin JA, 2002, NATL VITAL STAT REPO, V50
[10]   The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS) [J].
McElhatton, PR ;
Garbis, HM ;
Elefant, E ;
Vial, T ;
Bellemin, B ;
Mastroiacovo, P ;
Arnon, J ;
RodriguezPinilla, E ;
Schaefer, C ;
Pexieder, T ;
Merlob, P ;
DalVerme, S .
REPRODUCTIVE TOXICOLOGY, 1996, 10 (04) :285-294